Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30375142 | 1.00 | MAPT (0.63) | MAPTPOLBKDM4EGLAALDH1A1 | |
| SCHEMBL2703001 | 0.89 | MAPT (0.56) | MAPTPOLBKDM4EGLAALDH1A1 | |
| SCHEMBL3549901 | 0.83 | MAPT (0.58) | MAPTPOLBKDM4EGLAALDH1A1 | |
| SCHEMBL3908082 | 0.83 | MAPT (0.58) | MAPTPOLBKDM4EGLAALDH1A1 | |
| SCHEMBL30089256 | 0.83 | MAPT (0.58) | MAPTPOLBKDM4EGLAALDH1A1 | |
| SCHEMBL2703087 | 0.83 | KEAP1 (0.59) | MAPTKDM4EALDH1A1TP53MAPK1 | |
| SCHEMBL5282720 | 0.82 | MAPT (0.59) | MAPTALDH1A1TP53NPC1HPGD | |
| SCHEMBL29664874 | 0.82 | MAPT (0.59) | MAPTALDH1A1TP53NPC1HPGD | |
| SCHEMBL28171560 | 0.81 | KDM4E (0.73) | MAPTPOLBKDM4EGLAALDH1A1 | |
| SCHEMBL332634 | 0.80 | RECQL (0.71) | MAPTPOLBKDM4EGLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10092786-B2 | Fire extinguishing composition comprising aldoketones compound | XI'AN WESTPEACE FIRE TECHNOLOGY CO., LTD. (CN) | 2018-10-09 | — | — | US | claimed |
| US-20160332016-A1 | Fire Extinguishing Composition Comprising Aldoketones Compound | NANO FIRE, LLC | 2016-11-17 | — | — | US | claimed |
| US-20250319096-A1 | METHODS AND COMPOUNDS FOR TREATING INFLAMMATION | PANTHERICS INCORPERATED (US) | 2025-10-16 | — | — | US | disclosed |
| US-20240279232-A1 | USE OF SUBSTITUTED 5-(4-METHYL-6-PHENYL-4H-BENZO[F]IMIDAZO[1,5-A][1,4] DIAZEPIN-3-YL)-1,2,4-OXADIAZOLES IN THE TREATMENT OF INFLAMMATORY CONDITIONS | UWM RESEARCH FOUNDATION, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4299126-A2 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3160969-B1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116102558-A | Novel benzodiazepine compound, preparation method and application thereof | 中国药科大学 | 2023-05-12 | — | — | CN | disclosed |
| WO-2023059443-A1 | METHODS AND COMPOUNDS FOR TREATING INFLAMMATION | PANTHERICS INCORPORATED (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4129297-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM Research Foundation, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-5481005-A | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1996-01-02 | — | — | US | disclosed |
| US-5397801-A | Affinity for vasopressin and ocytocin receptors; disorders of nervous, cardiovascular and gastrointestinal systems | SANOFI (FR) | 1995-03-14 | — | — | US | disclosed |
| US-5338755-A | Have affinity for vasopressin and ocytocin receptors; intermediates for drugs that act on central nervous system | ELF SANOFI (FR) | 1994-08-16 | — | — | US | disclosed |
| WO-1994004592-A1 | PHOTOCONDUCTIVE POLYMERS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-03-03 | — | — | WO | disclosed |
| EP-0004024-B1 | METHOD FOR PREPARING 3-HYDROXY-6-PHENYL-1,2,3,4-TETRAHYDRO-1,5-BENZODIAZOCINES | Kali-Chemie Pharma GmbH (DE) | 1982-02-24 | — | — | EP | disclosed |
| US-4169150-A | MUSCLE RELAXANTS, HYPNOSIS, ANTICONVULSANTS, SEDATIVES | TEIJIN LIMITED (JP) | 1979-09-25 | — | — | US | disclosed |
| EP-0004024-A2 | Method for preparing 3-hydroxy-6-phenyl-1,2,3,4-tetrahydro-1,5-benzodiazocines | Kali-Chemie Pharma GmbH (DE) | 1979-09-19 | — | — | EP | disclosed |
| US-3947466-A | ANTIDEPRESSANTS, ANTIANXIETY | THE UPJOHN COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
| US-3941803-A | 2-(Imidazol-1-yl)benzophenones | THE UPJOHN COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | GABRA5, CHRNA5, GABRA1 | MAPT 101/4885POLB 2725/4885KDM4E 3145/4885 |
| US-20250319096-A1 | METHODS AND COMPOUNDS FOR TREATING INFLAMMATION | MMP8, TNF, MPO | MAPT 2277/4885POLB 2554/4885KDM4E 3966/4885 |
| US-20240279232-A1 | USE OF SUBSTITUTED 5-(4-METHYL-6-PHENYL-4H-BENZO[F]IMIDAZO[1,5-A][1,4] DIAZEPIN-3-YL)-1,2,4-OXADIAZOLES IN THE TREATMENT OF INFLAMMATORY CONDITIONS | OPRK1, OPRD1, OPRM1 | MAPT 3380/4885POLB 4133/4885KDM4E 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.